Genre
Journal articleDate
2021-05-24Author
Hale, MartinGarofoli, Mark
Raffa, Robert B.
Department
Pharmeceutical SciencesPermanent link to this record
http://hdl.handle.net/20.500.12613/7020
Metadata
Show full item recordDOI
https://doi.org/10.2147/jpr.s305146Abstract
Health care providers in the United States are facing challenges in selecting appropriate medication for patients with acute and chronic pain in the midst of the current opioid crisis and COVID-19 pandemic. When compared with conventional opioids, the partial μ-opioid receptor agonist buprenorphine has unique pharmacologic properties that may be more desirable for pain management. The formulations of buprenorphine approved by the US Food and Drug Administration for pain management include intravenous injection, transdermal patch, and buccal film. A comparison of efficacy and safety data from studies of buprenorphine and conventional opioids suggests that buprenorphine may be a better-tolerated treatment option for many patients that provides similar or superior analgesia. Our benefit-risk assessment in this narrative review suggests that health care providers should consider that buprenorphine may be an appropriate alternative for pain management over other opioids.Citation
Hale M, Garofoli M, Raffa RB. Benefit-Risk Analysis of Buprenorphine for Pain Management. J Pain Res. 2021;14:1359-1369, https://doi.org/10.2147/JPR.S305146Citation to related work
Dove Medical PressHas part
Journal of Pain Research, Vol. 14ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.eduae974a485f413a2113503eed53cd6c53
http://dx.doi.org/10.34944/dspace/7001
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Attribution-NonCommercial CC BY-NC